Meghan Mooradian, MD, discusses findings and implications of the phase 2 NEO-MEL-T study.
Meghan Mooradian, MD
Advertisement
Meghan Mooradian, MD, is a medical oncologist at Massachusetts General Hospital.
Articles by Meghan Mooradian, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
